Oral Green Tea Extract and Milk Thistle Extract to Colorectal Cancer Patients Undergoing Resection - Full Text View

Purpose

Colorectal cancer is the third most common form of cancer found in the United States. To date surgical resection provides the best chance for cure. Unfortunately, despite "curative" surgery, tumor recurrences develop in 30-40% of patients from either unforeseen residual metastases or from viable tumor cells shed into the circulation before or at the time of surgery. There is evidence from both humans and mice suggesting that tumor growth is stimulated after surgery for a period of time.

This study calls for the administration of a green tea extract and a milk thistle extract, two orally ingested supplements, during the week immediately before and weeks after your surgery. It is not the current standard of care to give anti-cancer drugs during the perioperative period. The basic idea behind this study is that it should be beneficial to inhibit cancer growth in the days leading up to and following surgery. Why is this the case?

It makes sense to limit or inhibit tumor growth before surgery with drugs provided it can be done safely and does not interfere with the surgery. It is also logical to give anti-cancer drugs after surgery because, unfortunately, about 35 percent of colorectal cancer patients, after resection, have hidden tumor cells that remain in the body. There is also strong human evidence that tumor growth is stimulated during the first month after tumor resection as a result of the surgical injuries and the healing process. Therefore, there is good reason to give anti-cancer drugs as soon as possible after surgery in order to offset some of surgery's negative effects.

Although both supplements have been given safely to a wide variety of patients with a number of different medical problems, the two supplements together have never been given to cancer patients during the weeks just before and following surgery. We hypothesize that the administration of these two supplements together will be safe in the period surrounding colorectal cancer surgery.

Condition	Intervention	Phase
Colon Cancer	Drug: Green Tea and Milk Thistle Supplements	Phase 1


Study Type:	Interventional
Study Design:	Intervention Model: Single Group Assignment Masking: No masking Primary Purpose: Treatment
Official Title:	Perioperative Administration of Oral Green Tea Extract/Milk Thistle Extract to Colorectal Cancer Patients Undergoing Colorectal Cancer Resection, a Phase 1 Study

Resource links provided by NLM:

MedlinePlus related topics: Dietary Supplements

Drug Information available for: Milk Thistle extract Camellia sinensis

U.S. FDA Resources

Further study details as provided by St. Luke's-Roosevelt Hospital Center:

Primary Outcome Measures:

Number of patients with adverse events or complications [ Time Frame: 60 days ]


Estimated Enrollment:	30
Study Start Date:	July 2011
Estimated Study Completion Date:	July 2018
Estimated Primary Completion Date:	June 2018 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
Experimental: Green Tea and Milk Thistle Supplements Patients will receive green tea extract and milk thistle extract supplements for one week prior to surgery and for 30 days after surgery.	Drug: Green Tea and Milk Thistle Supplements Green Tea Extract: 3,200 mg per day Milk thistle extract with phosphatidylcholine: 2,700 mg per day Other Names: Green Tea Extract: EGCg Milk Thistle Extract: Siliphos

Detailed Description:

Green tea extract and Silibinin (from the milk thistle plant) have both been shown in experimental studies to have anti-cancer effects as well as limited toxicity. Epigallocatechin-3-gallate (EGCG) is the major active catechin in green tea; it has been shown to prevent and limit tumor growth in murine models1-3. Silymarin, which is extracted from the seeds of the milk thistle plant, is used clinically as a hepatoprotective agent in Europe4. Its major active component, Silibinin, is well-tolerated and largely free of adverse effects5-6. In recent studies, Silibinin has been shown to inhibit the growth of a number of cancers in mouse models, including lung7, bladder8, liver9, prostate10, and colon11-12. Silibinin and EGCG have similar anti-neoplastic mechanisms including: 1) cell cycle arrest via upregulation of P21 and P27 and downregulation of CDK, 2) induction of apoptosis via Caspase-3 activation and cleavage of poly (ADP-ribose) polymerase (PARP), and 3) suppression of angiogenesis and metastasis via inhibition of vascular endothelial growth factor (VEGF) and matrix metalloproteinase (MMP-9)

Eligibility


Ages Eligible for Study:	18 Years to 85 Years (Adult, Senior)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Patients must be age 18 to 85 years
Patient must have biopsy proven colon or rectal cancer
Cancer should be judged to be stage 1 to 3 based on preoperative staging
Patients may be any race and any gender

Exclusion Criteria:

Patients with cancer judged to be stage 4 are not eligible
Patients undergoing emergency surgery for cancer are not eligible
Patients who are immunosuppressed or taking immunosuppressive medications (steroids or chemotherapeutic agents) are not eligible
Patients with Crohn's disease or ulcerative colitis are not eligible
Patients with other malignancies are not eligible
Patients who are taking part in other neoadjuvant and early adjuvant chemotherapy trials are not eligible

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01239095

Contacts


Contact: Richard L Whelan, MD	(212) 523-8172	rwhelan@chpnet.org

Locations


United States, New York
Mount Sinai St. Luke's Roosevelt Hospital Center	Recruiting
New York, New York, United States, 10019
Contact: Richard Whelan, MD 212-523-8172
Principal Investigator: Richard L Whelan, MD

Sponsors and Collaborators

St. Luke's-Roosevelt Hospital Center

Investigators


Principal Investigator:	Richard L Whelan, MD	Mount Sinai St. Luke's Roosevelt Hospital

More Information


Responsible Party:	St. Luke's-Roosevelt Hospital Center
ClinicalTrials.gov Identifier:	NCT01239095 History of Changes
Other Study ID Numbers:	10-089
Study First Received:	November 9, 2010
Last Updated:	June 2, 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD:	No

Additional relevant MeSH terms:


Colorectal Neoplasms Intestinal Neoplasms Gastrointestinal Neoplasms Digestive System Neoplasms Neoplasms by Site Neoplasms	Digestive System Diseases Gastrointestinal Diseases Colonic Diseases Intestinal Diseases Rectal Diseases

ClinicalTrials.gov processed this record on July 26, 2017